NCT03639948 - Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

January 27, 2022

Study Completion Date

November 30, 2024

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

Carboplatin

Intravenous solution

DRUG

Docetaxel

Intravenous solution

DRUG

Pembrolizumab

Intravenous solution

DRUG

Pegfilgrastim

Injectable product

Trial Locations (9)

64064

The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit

64116

The University of Kansas Medical Center, North Kansas City

64154

The University of Kansas Cancer Center, North Clinic, Kansas City

66112

The University of Kansas Cancer Center, West Clinic, Kansas City

66205

The University of Kansas Cancer Center (KUCC), Fairway

The University of Kansas Cancer Center, Westwood Campus, Kansas City

University of Kansas Cancer Center, Kansas City

66210

The University of Kansas Cancer Center, Overland Park Clinic, Overland Park

75246

Texas Oncology- Baylor, Dallas

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Kansas Medical Center

OTHER